» Articles » PMID: 12102655

Binding of C-reactive Protein to Modified Low-density-lipoprotein Particles: Identification of Cholesterol As a Novel Ligand for C-reactive Protein

Overview
Journal Biochem J
Specialty Biochemistry
Date 2002 Jul 10
PMID 12102655
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

C-reactive protein (CRP), an acute-phase reactant, is present in atherosclerotic human arterial intima in association with lipids. In the present work we studied interactions between CRP and LDL on microtitre wells, where either CRP or LDL was immobilized. LDL was modified by vortex-mixing, oxidation, or by lipolysis with phospholipase A(2) or with sphingomyelinase or a combination of trypsin and cholesterol esterase. We found that CRP bound only to LDL modified by trypsin/cholesterol esterase or by sphingomyelinase and that this binding was Ca(2+)-dependent. In these two forms of modified LDL, non-esterified cholesterol was susceptible to cholesterol oxidase, indicating exposure of non-esterified cholesterol on particle surfaces and suggesting a role for non-esterified cholesterol in mediating CRP binding. Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. The binding was Ca(2+)-dependent and could be competed out with phosphocholine. Taken together, these findings suggest that CRP can bind to modified lipoproteins, notably to the non-esterified cholesterol on their surface. These interactions may be related to the suggested role of CRP in the local inflammation present in atherosclerotic plaques.

Citing Articles

C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.

Kirkgoz K Rev Cardiovasc Med. 2024; 24(10):297.

PMID: 39077585 PMC: 11262456. DOI: 10.31083/j.rcm2410297.


C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.

Mouliou D Diseases. 2023; 11(4).

PMID: 37873776 PMC: 10594506. DOI: 10.3390/diseases11040132.


An overview on serum lectins.

Beulaja Manikandan S, Manikandan R, Arumugam M, Mullainadhan P Heliyon. 2020; 6(8):e04623.

PMID: 32923708 PMC: 7475231. DOI: 10.1016/j.heliyon.2020.e04623.


Functionality of C-Reactive Protein for Atheroprotection.

Singh S, Agrawal A Front Immunol. 2019; 10:1655.

PMID: 31379851 PMC: 6646712. DOI: 10.3389/fimmu.2019.01655.


Recognition functions of pentameric C-reactive protein in cardiovascular disease.

Agrawal A, Gang T, Rusinol A Mediators Inflamm. 2014; 2014:319215.

PMID: 24948846 PMC: 4052174. DOI: 10.1155/2014/319215.


References
1.
Pentikainen M, Oorni K, Ala-Korpela M, Kovanen P . Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med. 2000; 247(3):359-70. DOI: 10.1046/j.1365-2796.2000.00655.x. View

2.
Gershov D, Kim S, Brot N, Elkon K . C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000; 192(9):1353-64. PMC: 2193350. DOI: 10.1084/jem.192.9.1353. View

3.
Hevonoja T, Pentikainen M, Hyvonen M, Kovanen P, Ala-Korpela M . Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta. 2000; 1488(3):189-210. DOI: 10.1016/s1388-1981(00)00123-2. View

4.
Zwaka T, Hombach V, Torzewski J . C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001; 103(9):1194-7. DOI: 10.1161/01.cir.103.9.1194. View

5.
Hakala J, Oorni K, Pentikainen M, Hurt-Camejo E, Kovanen P . Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol. 2001; 21(6):1053-8. DOI: 10.1161/01.atv.21.6.1053. View